Catalent, Inc. (NYSE:CTLT) Sees Large Growth in Short Interest

Catalent, Inc. (NYSE:CTLT) was the recipient of a large increase in short interest during the month of July. As of July 15th, there was short interest totalling 10,550,000 shares, an increase of 22.5% from the June 30th total of 8,610,000 shares. Based on an average daily trading volume, of 1,720,000 shares, the days-to-cover ratio is currently 6.1 days.

Insiders Place Their Bets

In other news, CEO Alessandro Maselli sold 9,088 shares of the company’s stock in a transaction on Monday, July 29th. The stock was sold at an average price of $58.76, for a total value of $534,010.88. Following the sale, the chief executive officer now directly owns 177,521 shares in the company, valued at $10,431,133.96. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other Catalent news, CEO Alessandro Maselli sold 9,088 shares of the firm’s stock in a transaction dated Monday, July 29th. The shares were sold at an average price of $58.76, for a total transaction of $534,010.88. Following the sale, the chief executive officer now directly owns 177,521 shares of the company’s stock, valued at approximately $10,431,133.96. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Matti Masanovich sold 2,993 shares of the business’s stock in a transaction that occurred on Monday, July 8th. The shares were sold at an average price of $56.74, for a total transaction of $169,822.82. Following the completion of the transaction, the chief financial officer now directly owns 33,871 shares of the company’s stock, valued at approximately $1,921,840.54. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 13,482 shares of company stock valued at $779,852. Corporate insiders own 0.31% of the company’s stock.

Institutional Trading of Catalent

Several institutional investors have recently added to or reduced their stakes in CTLT. Vanguard Group Inc. boosted its holdings in shares of Catalent by 1.1% in the 1st quarter. Vanguard Group Inc. now owns 20,405,181 shares of the company’s stock valued at $1,151,872,000 after buying an additional 218,682 shares during the period. Capital World Investors boosted its stake in Catalent by 6.1% in the fourth quarter. Capital World Investors now owns 19,079,994 shares of the company’s stock valued at $857,264,000 after acquiring an additional 1,098,474 shares during the period. Nomura Holdings Inc. grew its holdings in shares of Catalent by 149.4% during the fourth quarter. Nomura Holdings Inc. now owns 11,487,342 shares of the company’s stock valued at $516,126,000 after purchasing an additional 6,881,914 shares during the last quarter. Cadian Capital Management LP raised its position in shares of Catalent by 14.3% during the 4th quarter. Cadian Capital Management LP now owns 6,064,384 shares of the company’s stock worth $272,473,000 after purchasing an additional 759,600 shares during the period. Finally, Capital International Investors raised its position in shares of Catalent by 1.2% during the 4th quarter. Capital International Investors now owns 2,994,467 shares of the company’s stock worth $134,541,000 after purchasing an additional 34,856 shares during the period.

Analysts Set New Price Targets

Several equities analysts recently commented on the company. StockNews.com initiated coverage on Catalent in a research note on Wednesday, July 24th. They issued a “sell” rating for the company. Stephens reissued an “equal weight” rating and issued a $63.50 target price on shares of Catalent in a research report on Thursday, April 4th. Royal Bank of Canada restated a “sector perform” rating and issued a $63.50 target price on shares of Catalent in a report on Thursday, July 11th. Finally, Barclays increased their price target on shares of Catalent from $47.00 to $63.00 and gave the stock an “equal weight” rating in a research note on Friday, June 28th. Two research analysts have rated the stock with a sell rating, seven have issued a hold rating and three have given a buy rating to the company’s stock. Based on data from MarketBeat, Catalent presently has a consensus rating of “Hold” and an average target price of $55.65.

Catalent Stock Up 0.1 %

Catalent stock traded up $0.06 during midday trading on Tuesday, hitting $59.04. The stock had a trading volume of 2,095,975 shares, compared to its average volume of 2,204,608. The business has a fifty day moving average price of $56.29 and a 200 day moving average price of $55.84. Catalent has a 12 month low of $31.80 and a 12 month high of $60.20. The stock has a market cap of $10.69 billion, a P/E ratio of -9.68, a P/E/G ratio of 2.42 and a beta of 1.16. The company has a current ratio of 2.51, a quick ratio of 1.77 and a debt-to-equity ratio of 1.37.

Catalent (NYSE:CTLT) last issued its earnings results on Wednesday, May 8th. The company reported ($0.15) EPS for the quarter, missing the consensus estimate of $0.21 by ($0.36). The firm had revenue of $1.07 billion during the quarter, compared to analyst estimates of $1.11 billion. Catalent had a negative return on equity of 2.73% and a negative net margin of 26.61%. Research analysts predict that Catalent will post -0.17 EPS for the current year.

Catalent Company Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.